Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

Steffi Oesterreich, N. Lynn Henry, Kelley M. Kidwell, Catherine H. Van Poznak, Todd Skaar, Jessica Dantzer, Lang Li, Thomas N. Hangartner, Munro Peacock, Anne T. Nguyen, James M. Rae, Zeruesenay Desta, Santosh Philips, Anna Maria Storniolo, Vered Stearns, Daniel F. Hayes, David A. Flockhart

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesized that single nucleotide polymorphisms (SNP) predict effects of AIs on bone turnover. Early stage HR-positive breast cancer patients were enrolled in a randomized trial of exemestane versus letrozole. Effects of AI on bone mineral density (BMD) and bone turnover markers (BTM), and associations between SNPs in 24 candidate genes and changes in BMD or BTM were determined. Of the 503 enrolled patients, paired BMD data were available for 123 and 101 patients treated with letrozole and exemestane, respectively, and paired BTM data were available for 175 and 173 patients, respectively. The mean change in lumbar spine BMD was significantly greater for letrozole-treated (−3.2 %) compared to exemestane-treated patients (−1.0 %) (p = 0.0016). Urine N-telopeptide was significantly increased in patients treated with exemestane (p = 0.001) but not letrozole. Two SNPs (rs4870061 and rs9322335) in ESR1 and one SNP (rs10140457) in ESR2 were associated with decreased BMD in letrozole-treated patients. In the exemestane-treated patients, SNPs in ESR1 (Rs2813543) and CYP19A1 (Rs6493497) were associated with decreased bone density. Exemestane had a less negative impact on bone density compared to letrozole, and the effects of AI therapy on bone may be impacted by genetic variants in the ER pathway.

Original languageEnglish (US)
Pages (from-to)263-273
Number of pages11
JournalBreast Cancer Research and Treatment
Volume154
Issue number2
DOIs
StatePublished - Nov 1 2015

Fingerprint

exemestane
letrozole
Bone Remodeling
Bone Density
Aromatase Inhibitors
Bone and Bones
Single Nucleotide Polymorphism
Hormones
Breast Neoplasms

Keywords

  • Aromatase inhibitors
  • Bone health
  • Breast cancer
  • Pharmacogenomics
  • Polymorphism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. / Oesterreich, Steffi; Henry, N. Lynn; Kidwell, Kelley M.; Van Poznak, Catherine H.; Skaar, Todd; Dantzer, Jessica; Li, Lang; Hangartner, Thomas N.; Peacock, Munro; Nguyen, Anne T.; Rae, James M.; Desta, Zeruesenay; Philips, Santosh; Storniolo, Anna Maria; Stearns, Vered; Hayes, Daniel F.; Flockhart, David A.

In: Breast Cancer Research and Treatment, Vol. 154, No. 2, 01.11.2015, p. 263-273.

Research output: Contribution to journalArticle

Oesterreich, S, Henry, NL, Kidwell, KM, Van Poznak, CH, Skaar, T, Dantzer, J, Li, L, Hangartner, TN, Peacock, M, Nguyen, AT, Rae, JM, Desta, Z, Philips, S, Storniolo, AM, Stearns, V, Hayes, DF & Flockhart, DA 2015, 'Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover', Breast Cancer Research and Treatment, vol. 154, no. 2, pp. 263-273. https://doi.org/10.1007/s10549-015-3608-8
Oesterreich, Steffi ; Henry, N. Lynn ; Kidwell, Kelley M. ; Van Poznak, Catherine H. ; Skaar, Todd ; Dantzer, Jessica ; Li, Lang ; Hangartner, Thomas N. ; Peacock, Munro ; Nguyen, Anne T. ; Rae, James M. ; Desta, Zeruesenay ; Philips, Santosh ; Storniolo, Anna Maria ; Stearns, Vered ; Hayes, Daniel F. ; Flockhart, David A. / Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. In: Breast Cancer Research and Treatment. 2015 ; Vol. 154, No. 2. pp. 263-273.
@article{002675973950471b838166745e0fa848,
title = "Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover",
abstract = "Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesized that single nucleotide polymorphisms (SNP) predict effects of AIs on bone turnover. Early stage HR-positive breast cancer patients were enrolled in a randomized trial of exemestane versus letrozole. Effects of AI on bone mineral density (BMD) and bone turnover markers (BTM), and associations between SNPs in 24 candidate genes and changes in BMD or BTM were determined. Of the 503 enrolled patients, paired BMD data were available for 123 and 101 patients treated with letrozole and exemestane, respectively, and paired BTM data were available for 175 and 173 patients, respectively. The mean change in lumbar spine BMD was significantly greater for letrozole-treated (−3.2 {\%}) compared to exemestane-treated patients (−1.0 {\%}) (p = 0.0016). Urine N-telopeptide was significantly increased in patients treated with exemestane (p = 0.001) but not letrozole. Two SNPs (rs4870061 and rs9322335) in ESR1 and one SNP (rs10140457) in ESR2 were associated with decreased BMD in letrozole-treated patients. In the exemestane-treated patients, SNPs in ESR1 (Rs2813543) and CYP19A1 (Rs6493497) were associated with decreased bone density. Exemestane had a less negative impact on bone density compared to letrozole, and the effects of AI therapy on bone may be impacted by genetic variants in the ER pathway.",
keywords = "Aromatase inhibitors, Bone health, Breast cancer, Pharmacogenomics, Polymorphism",
author = "Steffi Oesterreich and Henry, {N. Lynn} and Kidwell, {Kelley M.} and {Van Poznak}, {Catherine H.} and Todd Skaar and Jessica Dantzer and Lang Li and Hangartner, {Thomas N.} and Munro Peacock and Nguyen, {Anne T.} and Rae, {James M.} and Zeruesenay Desta and Santosh Philips and Storniolo, {Anna Maria} and Vered Stearns and Hayes, {Daniel F.} and Flockhart, {David A.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s10549-015-3608-8",
language = "English (US)",
volume = "154",
pages = "263--273",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

AU - Oesterreich, Steffi

AU - Henry, N. Lynn

AU - Kidwell, Kelley M.

AU - Van Poznak, Catherine H.

AU - Skaar, Todd

AU - Dantzer, Jessica

AU - Li, Lang

AU - Hangartner, Thomas N.

AU - Peacock, Munro

AU - Nguyen, Anne T.

AU - Rae, James M.

AU - Desta, Zeruesenay

AU - Philips, Santosh

AU - Storniolo, Anna Maria

AU - Stearns, Vered

AU - Hayes, Daniel F.

AU - Flockhart, David A.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesized that single nucleotide polymorphisms (SNP) predict effects of AIs on bone turnover. Early stage HR-positive breast cancer patients were enrolled in a randomized trial of exemestane versus letrozole. Effects of AI on bone mineral density (BMD) and bone turnover markers (BTM), and associations between SNPs in 24 candidate genes and changes in BMD or BTM were determined. Of the 503 enrolled patients, paired BMD data were available for 123 and 101 patients treated with letrozole and exemestane, respectively, and paired BTM data were available for 175 and 173 patients, respectively. The mean change in lumbar spine BMD was significantly greater for letrozole-treated (−3.2 %) compared to exemestane-treated patients (−1.0 %) (p = 0.0016). Urine N-telopeptide was significantly increased in patients treated with exemestane (p = 0.001) but not letrozole. Two SNPs (rs4870061 and rs9322335) in ESR1 and one SNP (rs10140457) in ESR2 were associated with decreased BMD in letrozole-treated patients. In the exemestane-treated patients, SNPs in ESR1 (Rs2813543) and CYP19A1 (Rs6493497) were associated with decreased bone density. Exemestane had a less negative impact on bone density compared to letrozole, and the effects of AI therapy on bone may be impacted by genetic variants in the ER pathway.

AB - Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesized that single nucleotide polymorphisms (SNP) predict effects of AIs on bone turnover. Early stage HR-positive breast cancer patients were enrolled in a randomized trial of exemestane versus letrozole. Effects of AI on bone mineral density (BMD) and bone turnover markers (BTM), and associations between SNPs in 24 candidate genes and changes in BMD or BTM were determined. Of the 503 enrolled patients, paired BMD data were available for 123 and 101 patients treated with letrozole and exemestane, respectively, and paired BTM data were available for 175 and 173 patients, respectively. The mean change in lumbar spine BMD was significantly greater for letrozole-treated (−3.2 %) compared to exemestane-treated patients (−1.0 %) (p = 0.0016). Urine N-telopeptide was significantly increased in patients treated with exemestane (p = 0.001) but not letrozole. Two SNPs (rs4870061 and rs9322335) in ESR1 and one SNP (rs10140457) in ESR2 were associated with decreased BMD in letrozole-treated patients. In the exemestane-treated patients, SNPs in ESR1 (Rs2813543) and CYP19A1 (Rs6493497) were associated with decreased bone density. Exemestane had a less negative impact on bone density compared to letrozole, and the effects of AI therapy on bone may be impacted by genetic variants in the ER pathway.

KW - Aromatase inhibitors

KW - Bone health

KW - Breast cancer

KW - Pharmacogenomics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84947490690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947490690&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3608-8

DO - 10.1007/s10549-015-3608-8

M3 - Article

VL - 154

SP - 263

EP - 273

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -